|Bid||2.90 x 1000|
|Ask||3.05 x 1000|
|Day's Range||2.90 - 3.08|
|52 Week Range||2.90 - 6.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.58|
Ziopharm has been stung by a series of clinical setbacks this year, and the company is now facing a serious cash crunch to boot.
Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ZIOPHARM ...
Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that it has enrolled the first patient in its Phase 1 clinical trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with recurrent glioblastoma (rGBM). “We are excited about the first-ever dosing of this combination and its potential to bring a potent and controlled anti-tumor immune response to glioblastoma,” said Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at Ziopharm. “By controlling interleukin 12, Ad-RTS-hIL-12 plus veledimex already has shown it can recruit killer T cells into the tumor and increase expression of checkpoints in this microenvironment.
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / Arrowhead Pharmaceuticals was seeing big gains in Monday's trading session after announcing that it has fully enrolled its phase 1 study of ARO-AAT, for alpha-1 ...
Ziopharm Oncology Inc. said Monday the U.S. Food and Drug Administration has placed a clinical hold on a Phase 1 trial of a treatment for cancer. The trial sought to evaluate CD19-specific CAR-T therapies made with Sleeping Beauty technology as an investigational treatment for patients with relapsed or refractory, CD19 leukemias and lymphomas, the company said in a statement. Ziopharm specializes in developing therapies to treat a range of cancers, using Sleeping Beauty, a non-viral approach to genetically modify chimeric antigen receptor (CAR(+) ) and T-cell receptor (TCR(+) ) T cells, which target specific antigens in blood cancers and neoantigens in solid tumors.
Ziopharm, Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and The University of Texas MD Anderson Cancer Center, the IND sponsor, are seeking to conduct a clinical trial to evaluate CAR+ T cells manufactured with Sleeping Beauty technology as an investigational treatment for patients with relapsed or refractory, CD19+ leukemias and lymphomas. CAR+ T cells very-rapidly manufactured with the Sleeping Beauty platform for this third-generation trial are designed to co-express CD19-specific chimeric antigen receptor, or CAR, membrane-bound interleukin 15 and a safety switch.
Shares in Needham, Massachusetts headquartered Verastem Inc. saw a decline of 3.56%, ending Monday's trading session at $5.14. The stock recorded a trading volume of 2.58 million shares, which was higher than its three months average volume of 1.23 million shares.
-Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers- Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20 mg veledimex cohort who received ...
NEW YORK, NY / ACCESSWIRE / May 31, 2018 / U.S. equities rebounded on Wednesday, lifted by strong performance from the energy sector and worries over Italy's political crisis eased. The Dow Jones Industrial ...
-Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers. -IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients ...
NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of root9B ...
Both clinical-stage biotechs have cutting-edge cancer therapies in their pipelines. But which stock wins in a head-to-head matchup?
On a per-share basis, the Boston-based company said it had a loss of 15 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (ZIOP), today announced financial results for the first quarter ended March 31, 2018, and provided an update on the Company’s recent activities. “The landscapes of CAR-T therapies and the use of cytokines are playing out as anticipated,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. Dr. Cooper continued, “Immune-stimulatory cytokines have gained significant momentum as potential combination therapies with immune checkpoint inhibitors.
The webcast will be recorded and available for replay on the Company's website for two weeks. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.